Nitric-oxide Coated Bioactive Titanium Stents: Safer and More Effective Than Second-generation Drug-eluting Stents?

2014 ◽  
Vol 67 (7) ◽  
pp. 511-513
Author(s):  
Manel Sabaté ◽  
Salvatore Brugaletta
Keyword(s):  
Nitric Oxide ◽  
Second Generation ◽  
Drug Eluting Stents ◽  
Drug Eluting

Approved drug-eluting stents: second generation

2012 ◽  
pp. 32-43
Author(s):  
Giampaolo Niccoli ◽  
Gregory A Sgueglia
Keyword(s):  
Second Generation ◽  
Drug Eluting Stents ◽  
Drug Eluting

scholarly journals Angiographic control versus ischaemia-driven management of patients undergoing percutaneous revascularisation of the unprotected left main coronary artery with second-generation drug-eluting stents: rationale and design of the PULSE trial

Open Heart ◽  
2020 ◽  
Vol 7 (2) ◽  
pp. e001253
Author(s):  
Ovidio De Filippo ◽  
Matteo Bianco ◽  
Matteo Tebaldi ◽  
Mario Iannaccone ◽  
Luca Gaido ◽  
...  
Keyword(s):  
Second Generation ◽  
Controlled Trial ◽  
Drug Eluting Stents ◽  
Major Adverse Cardiovascular Events ◽  
Relative Reduction ◽  
Left Main ◽  
Bleeding Events ◽  
Open Label ◽  
Drug Eluting

BackgroundThe role of planned angiographic control (PAC) over a conservative management driven by symptoms and ischaemia following percutaneous coronary intervention (PCI) of the unprotected left main (ULM) with second-generation drug-eluting stents remains controversial. PAC may timely detect intrastent restenosis, but it is still unclear if this translated into improved prognosis.Methods and analysisPULSE is a prospective, multicentre, open-label, randomised controlled trial. Consecutive patients treated with PCI on ULM will be included, and after the index revascularisation patients will be randomised to PAC strategy performed with CT coronary after 6 months versus a conservative symptoms and ischaemia-driven follow-up management. Follow-up will be for at least 18 months from randomisation. Major adverse cardiovascular events at 18 months (a composite endpoint including death, cardiovascular death, myocardial infarction (MI) (excluding periprocedural MI), unstable angina, stent thrombosis) will be the primary efficacy outcome. Secondary outcomes will include any unplanned target lesion revascularisation (TLR) and TLR driven by PAC. Safety endpoints embrace worsening of renal failure and bleeding events. A sample size of 550 patients (275 per group) is required to have a 80% chance of detecting, as significant at the 5% level, a 7.5% relative reduction in the primary outcome.Trial registration numberNCT04144881

scholarly journals SHORT VERSUS LONG DURATION OF DUAL ANTIPLATELET THERAPY AFTER SECOND GENERATION DRUG-ELUTING STENTS IMPLANTATION IN DIABETICS

2021 ◽  
Vol 77 (18) ◽  
pp. 129
Author(s):  
Manesh Kumar Gangwani ◽  
Abeer Aziz ◽  
Shazib Sagheer ◽  
Priyanka Ahuja ◽  
Wade Lee-Smith ◽  
...  
Keyword(s):  
Antiplatelet Therapy ◽  
Second Generation ◽  
Dual Antiplatelet Therapy ◽  
Drug Eluting Stents ◽  
Long Duration ◽  
Drug Eluting

scholarly journals TCT-746 Outcomes by Total Stent Length in ACS PCI with Second Generation Drug-Eluting Stents: Results from the PROMETHEUS Study

2017 ◽  
Vol 70 (18) ◽  
pp. B316
Author(s):  
Asha Mahajan ◽  
Jaya Chandrasekhar ◽  
Samantha Sartori ◽  
Usman Baber ◽  
Birgit Vogel ◽  
...  
Keyword(s):  
Second Generation ◽  
Drug Eluting Stents ◽  
Stent Length ◽  
Drug Eluting
Sign in / Sign up

Export Citation Format

Share Document